Patents Issued in December 15, 2020
  • Patent number: 10864160
    Abstract: The invention relates to a beverage composition comprising: water; oxygen bubbles; a surfactant in an amount of between about 0.1% (v/v) and about 0.5% (v/v); one or more viscosity modifying agent(s) in an amount of between about 0.5% (v/v) and about 2.5% (v/v); and optionally citric acid in an amount of between about 0.1% (v/v) and about 0.5% (v/v). The invention further relates to compositions, methods of treatment for cancer, the composition for use in treatment of cancer, and the manufacture of the composition.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: December 15, 2020
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Eleanor Stride, Joshua Owen, Ray Averre
  • Patent number: 10864161
    Abstract: Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: December 15, 2020
    Assignee: American University of Sharjah
    Inventors: Ghaleb Husseini, Mohammad Al-Sayah, Amal Elsadig
  • Patent number: 10864162
    Abstract: Methods for making particles, such as nanoparticles, devices useful in the methods, and particles made by the method are described herein. The methods involves the use of microfluidic device, such that upon mixing solutions of the materials to form the particles (or a solution of the material or materials to form the particles and a non-solvent for the material or materials) at least two symmetrical microvortices are formed simultaneously. The method can be used to prepare polymeric or non-polymeric particles and hybrid particles, such as lipid-polymer hybrid particles, as well as such particles containing one or more agents associated with the particles.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 15, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: YongTae Kim, Zahi Fayad, Willem J. Mulder, Edward Fisher, Francois Fay, Omid C. Farokhzad, Robert Langer
  • Patent number: 10864163
    Abstract: The invention relates to methods for attaching therapeutic agents to structures produced by thermally induced phase separation as well as methods for coating devices and producing multi-layered microspheres.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 15, 2020
    Assignee: UCL Business LTD
    Inventor: Richard Michael Day
  • Patent number: 10864164
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of coated particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide; and form a discontinuous phase within the matrix material; which preferably provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and method of using said tablet to treat pain and other conditions.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 15, 2020
    Assignee: Grünenthal GmbH
    Inventors: Sebastian Schwier, Marcel Haupts, Lutz Barnscheid, Jana Pätz
  • Patent number: 10864165
    Abstract: An object of the present invention is to provide an orally disintegrating tablet (super-rapid disintegrating tablet) that is heavy and relatively thin, and has an extremely high disintegrability (short disintegration time), and a high tablet hardness, and to provide a simple method for the production of said super-rapid disintegrating tablet without such a complicated process as freeze-drying. This invention relates to an orally disintegrating tablet having a specific surface area of from 1.50 to 4.00 mm2/mg and a weight of from 100 to 300 mg, particularly having a disintegration time in water of 7 seconds or less and an oral disintegration time of 6 seconds or less, a method for the production of said orally disintegrating tablet, and to a disintegrative particulate composition for use in said method.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 15, 2020
    Assignee: DAICEL CORPORATION
    Inventors: Tomohito Okabayashi, Atsuhiro Uetomo, Naohiro Hashikawa, Takahiro Hiramura, Tetsuro Morita, Kimiko Ikeda
  • Patent number: 10864166
    Abstract: The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 ?g/mL at pH 6.8.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: December 15, 2020
    Assignee: Adare Pharmaceuticals, Inc.
    Inventors: Gopi Venkatesh, Luigi Boltri, Italo Colombo, Jin-Wang Lai, Flavio Fabiani, Luigi Mapelli
  • Patent number: 10864167
    Abstract: An improved process of making a benefit agent delivery particle and consumer products incorporating such particles are disclosed. The process comprises the steps of providing a first composition of water phase 1, water phase 2 and water phase 3. Water phase 1 comprises water and an initiator; water phase 2 comprises water, a water-soluble or dispersible amine(meth)acrylate or hydroxyl(meth)acrylate and a multifunctional (meth)acrylate. Water phase 3 comprises water, and carboxyalkyl(meth)acrylate and a base or quaternary ammonium acrylate. The first two water phases are combined to prereact the hydroxy- or amine(meth)acrylate and the multifunctional (meth)acrylate to form a multifunctional hydroxyl-amine(meth)acrylate pre-polymer.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: December 15, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Hanwei Zhang, Todd Arlin Schwantes, Katie Ann Hobart, Diane Jean Williamson
  • Patent number: 10864168
    Abstract: Provided are lipid membrane microcapsules encapsulating or containing bioactives, and methods of production and use.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: December 15, 2020
    Assignee: The Regents of the University of California
    Inventors: Nitin Nitin, Stephen Young, Jean Vandergheynst
  • Patent number: 10864169
    Abstract: Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: December 15, 2020
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Jae Moon Yang, Jung Hyun Kim, Jeong Hun Kim, Yoo Chan Hong, Won Seok Cho, Seung Yeon Hwang, Jin Suck Suh
  • Patent number: 10864170
    Abstract: Pharmaceutical composition containing poly(bile) acid (PBA) polymers for oral delivery of agent(s) show enhanced uptake by the pancreas, liver, and colon. These nanoparticles show significant retention in the pancreas and colon and are therefore useful for selective delivery. The examples demonstrate efficacy of oral administration of insulin to treat diabetes, and oral induction of tolerance by administration of insulin or ovalbumin in combination with rapamycin. Diabetic animals treated with the insulin or insulin with rapamycin showed normalization of blood glucose levels.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: December 15, 2020
    Assignee: YALE UNIVERSITY
    Inventors: Tarek M. Fahmy, Jung Seok Lee, Dongin Kim
  • Patent number: 10864171
    Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: December 15, 2020
    Assignee: NANEXA AB
    Inventors: Jan-Otto Carlsson, Anders Johansson, Marten Rooth
  • Patent number: 10864172
    Abstract: A transdermal patch is provided for use during oil delivery to a user's skin. The patch has a first foam member and a second foam member positioned adjacent the first foam member. An adhesive member is attached to the second foam member for securing the patch to a user's skin. A release liner covers and extends across the adhesive member. A gap can be formed between the first foam member and the second foam member and surrounds the first foam member. The first foam member has a thickness which is greater than a thickness of the second foam member.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: December 15, 2020
    Assignee: CHEMSULTANTS INTERNATIONAL INC.
    Inventors: Berryinne Decker, Keith Muny, Gary Avalon, Brian Buehner
  • Patent number: 10864173
    Abstract: A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodege
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 15, 2020
    Assignee: Mitochon Pharmaceuticals, Inc.
    Inventors: Robert Alonso, John Gerard Geisler
  • Patent number: 10864174
    Abstract: Composition of shogaols and related compounds from Zingiberaceae family of plants for improved iron metabolism in health and prevention iron overload in patients in need of nutritional and/or therapeutic approach to ameliorate iron-overload.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: December 15, 2020
    Inventor: Vladimir Badmaev
  • Patent number: 10864175
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 15, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10864176
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 15, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10864178
    Abstract: The present invention relates to a pharmaceutical composition for treating cancer, containing a polyphenol compound as an active ingredient. The pharmaceutical composition according to the present study is very effective for the treatment and prognosis-improvement of cancer stem cells or cancer tissues having a magnitude of cancer stem cells such as poorly differentiated cancer. Further, the polyphenol compound and a biguanide compound, and an anticancer agent were observed to remarkably increase inhibitory effects on the growth of cancerous cells when they were administered to cancerous cells in combination rather than individually, thus the composition is expected to find great applications in the cancer therapy field.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: December 15, 2020
    Inventors: Jae Ho Cheong, Soo Youl Kim
  • Patent number: 10864179
    Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: December 15, 2020
    Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Liqin Wang, Rodrigo Leite De Oliveira, Rene Bernards
  • Patent number: 10864180
    Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 15, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim
  • Patent number: 10864181
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: December 15, 2020
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Patent number: 10864182
    Abstract: Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: December 15, 2020
    Inventor: David Brown
  • Patent number: 10864183
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: December 15, 2020
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Stephen G. Machatha
  • Patent number: 10864184
    Abstract: Ketone supplementation, such as through use of precursors of beta-hydroxybutyrate (BHB) and acetoacetate (AcAc), increased blood levels of ketone bodies, increases blood flow and wound closure in ischemic young and aged fisher rats significantly earlier compared to standard diet in aged rats. In vitro experiments with ketone bodies demonstrate decreased mitochondrial and cytosolic ROS in young and aged primary human dermal fibroblasts (PHDF). Ketone bodies increased migration in young and aged PHDFs.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: December 15, 2020
    Assignee: University of South Florida
    Inventors: Dominic Paul D'Agostino, Shannon Kesl
  • Patent number: 10864185
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: December 15, 2020
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 10864186
    Abstract: The present invention relates to a method of synthesising sulforaphane by reacting a compound of formula (A) with an oxidizing agent in an aqueous solvent and in the presence of a catalyst. The invention further provides a method of synthesising a stabilised complex of sulforaphane and cyclodextrin by mixing the sulforaphane prepared by the methodology defined herein with cyclodextrin in an aqueous solvent.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: December 15, 2020
    Assignee: PHARMAGRA LABS, INC.
    Inventors: Sahadeva Reddy Damireddi, Kpakpo Ambrioise Akue, Jared K. Nelson, Albert Roger Frisbee, Peter Wyatt Newsome
  • Patent number: 10864187
    Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: December 15, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10864188
    Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial and/or anti-fungal composition comprising cinnamaldehyde, trans-2-methoxycinnamaldehyde, cinnamyl acetate and linalool. In particular this composition is intended for preventing and/or treating microbial infection in an animal.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: December 15, 2020
    Assignee: SEPTEOS
    Inventor: Nicolas Tesse
  • Patent number: 10864189
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of skin disorders. In particular, the application describes topical compositions and methods of treatments comprising the combined use of one or more cannabinoids, or use of an ingredient that works on the endocannabinoid system, such as but not limited to, Palmitoylethanolamide (PEA), polyolprepolymers and stem cell extract.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: December 15, 2020
    Inventor: Jenna Borok
  • Patent number: 10864190
    Abstract: The present invention relates to the combination of an antiandrogen with a vitamin K antagonist or with a ?-glutamyl carboxylase inhibitor for use in the treatment or prevention of an androgen receptor positive cancer, such as prostate cancer, or a hyperactive androgen receptor signaling disease/disorder. The invention also relates to a vitamin K antagonist or a ?-glutamyl carboxylase inhibitor for use in resensitizing an antiandrogen-resistant prostate cancer to the treatment with an antiandrogen. The invention further provides a pharmaceutical composition comprising an antiandrogen, a vitamin K antagonist or a ?-glutamyl carboxylase inhibitor, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 15, 2020
    Assignee: CEMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH
    Inventors: Stefan Kubicek, Marco Licciardello
  • Patent number: 10864191
    Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease with comorbid apathy comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 15, 2020
    Assignee: H. Lundbeck A/S
    Inventor: Karl Tomas Odergren
  • Patent number: 10864192
    Abstract: Compositions and methods for mitigating a pathology following brain trauma or at least a portion of a cascade of a pathology associated therewith, including compositions and methods for treating concussion or preventing the onset of anecrotic cell death in neurons. Exemplary compositions for treating concussion include an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and one or more pharmaceutically acceptable excipients. The one or more excipients can be combined with the active compound to form an extended, controlled-release medicament that delivers a therapeutic concentration of the active compound over a period of time.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: December 15, 2020
    Assignee: Aristea Translational Medicine Corporation
    Inventor: Robert E. Becker
  • Patent number: 10864193
    Abstract: The invention provides for spot-on formulations comprising fipronil in a high concentration for the treatment or prophylaxis of parasites of mammals and birds, and in particular, cats, dogs, horses, chickens, sheep and cattle with the aim of ridding these animals of all the parasites commonly encountered by birds and mammals. The invention also provides for effective and lasting destruction of ectoparasites, such as fleas, ticks, itch mites and lice, and of endoparasites, nematodes, such as filariae, and roundworms of the digestive tract of animals and humans.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 15, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: James Pate, Natalya Shub
  • Patent number: 10864194
    Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 15, 2020
    Assignee: Clementia Pharmaceuticals Inc.
    Inventors: Clarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
  • Patent number: 10864195
    Abstract: This invention provides topical localized formulations comprising an isoxazoline compound and a pharmaceutically or veterinary acceptable liquid carrier vehicle comprising N,N-diethyl-3-methylbenzamide as a solvent and an improved method for controlling, and preventing parasite infestation in animals.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 15, 2020
    Assignee: Intervet Inc.
    Inventors: Stefan Fuchs, Anja Regina Heckeroth, Ramona Müller, Heike Williams, Hartmut Zoller
  • Patent number: 10864196
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 15, 2020
    Assignees: Calico Life Sciences, LLC, AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • Patent number: 10864197
    Abstract: Methods of treatment comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising the compound of structure (I) or pharmaceutically acceptable salt thereof, are provided.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: December 15, 2020
    Assignee: RETROPHIN, INC.
    Inventors: Radko Komers, Alvin Shih
  • Patent number: 10864198
    Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
    Type: Grant
    Filed: July 30, 2017
    Date of Patent: December 15, 2020
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Gary Gordon
  • Patent number: 10864199
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: December 15, 2020
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 10864200
    Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: December 15, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ewelina Hegel, Hans-Peter Josel, Eloisa Lopez-Calle, Josef Roedl, Noah Weiss, Benjamin Tiemann
  • Patent number: 10864201
    Abstract: The present invention encompasses compounds of the formula I which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: December 15, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Martin Thomas Fleck, Hannes Fiepko Koolman
  • Patent number: 10864202
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: December 15, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10864203
    Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: December 15, 2020
    Assignee: BEIGENE, LTD.
    Inventors: Jing Song, Lai Wang, Kang Li, Tong Zhang, Lusong Luo, Min Wei, Zhiyu Tang, Guoliang Zhang, Changyou Zhou
  • Patent number: 10864204
    Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: December 15, 2020
    Assignee: SHENZHEN PHARMACIN CO., LTD.
    Inventors: Zeren Wang, Yulan Zhao, Lijiang Wang, Xiao Zhang, Jun Xu, Shunqin Chen, Meili Sun, Guisheng Jiang
  • Patent number: 10864205
    Abstract: The invention provides compositions and methods that are effective to improve NO production in vivo and/or to increase NO levels in blood. Such compositions and methods are useful to improve sexual function in males and females.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 15, 2020
    Assignee: Innovus Pharmaceuticals, Inc.
    Inventor: Bassam Damaj
  • Patent number: 10864206
    Abstract: The invention is directed to the treatment of tauopathic neurodegenerative conditions and the underlying processes thereof. Based on the discovery that Rhes acts as a negative regulator of normal tau clearance, the compositions and methods of the invention may be applied to inhibit Rhes and reduce pathogenic tau aggregation. Rhes may be disrupted by disrupting RAS2D gene expression or reducing the abundance of Rhes protein in neurons. Additionally, post-translational modifications of Rhes may be targeted, including the disruption of Rhes farnesylation by the administration of farnesyltransferase inhibitors.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 15, 2020
    Assignee: The Regents of the University of California
    Inventors: Kenneth Kosik, Israel Hernandez
  • Patent number: 10864207
    Abstract: The present invention herein discloses potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function. Particularly, the invention relates to synergistic nutritional composition comprising exogenous blend of N1-methyl nicotinamide chloride and standardized red spinach extract enriched with nitrate content along with pharmaceutically acceptable excipients, wherein N1-methyl nicotinamide salt and standardized red spinach extract enriched with nitrate content are present in the ratio of 1:0.5 to 1:8; and N1-methyl nicotinamide chloride and nitrate of standardized red spinach extract, are present in the ratio of 1:0.1 to 1:1. The present synergistic composition is useful for treating endothelial dysfunction such as hypertension, atherosclerosis, thrombosis, myocardial infarction, heart injury.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: December 15, 2020
    Assignee: Celagenex Research (India) Pvt. Ltd.
    Inventors: Dhiraj Dhamane, Rajendra Prasad Tongra
  • Patent number: 10864208
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 15, 2020
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 10864209
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: December 15, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10864210
    Abstract: The present invention provides a composition and a combined medication method for treating an enterovirus infection. In particular, the present invention provides a composition for inhibiting enteroviruses, wherein the composition at least contains an inhibitor of a 3D virus protein and an inhibitor of a capsid protein, or a combination of an inhibitor of a 3C protein and an inhibitor of a 3A protein.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: December 15, 2020
    Assignee: INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES
    Inventors: Gang Zou, Ralf Altmeyer, Yizhuo Wang